Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20286
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLassman, Andrew B-
dc.contributor.authorRoberts-Rapp, Lisa A-
dc.contributor.authorSokolova, Irina-
dc.contributor.authorSong, Minghao-
dc.contributor.authorPestova, Ekaterina-
dc.contributor.authorKular, Rupinder-
dc.contributor.authorMullen, Carolyn-
dc.contributor.authorZha, Zheng-
dc.contributor.authorLu, Xin-
dc.contributor.authorGomez, Erica-
dc.contributor.authorBhathena, Anahita-
dc.contributor.authorMaag, David-
dc.contributor.authorKumthekar, Priya-
dc.contributor.authorGan, Hui K-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorGuseva, Maria-
dc.contributor.authorHolen, Kyle D-
dc.contributor.authorAnsell, Peter-
dc.contributor.authorvan den Bent, Martin J-
dc.date2019-02-22-
dc.date.accessioned2019-03-04T22:04:13Z-
dc.date.available2019-03-04T22:04:13Z-
dc.date.issued2019-06-01-
dc.identifier.citationClinical Cancer Research 2019; 25(11): 3259-3265-
dc.identifier.issn1078-0432-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/20286-
dc.description.abstractPatients with glioblastoma (GBM) have a poor prognosis and are in desperate need of better therapies. As therapeutic decisions are increasingly guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing a potential therapeutic target, we systematically evaluated methods of assessing EGFR amplification by multiple assays. Specifically, we evaluated correlation between fluorescence in situ hybridization (FISH), a standard assay for detecting EGFR amplification, with other methods. Formalin-fixed, paraffin-embedded tumor samples were used for all assays. EGFR amplification was detected using FISH (N = 206) and whole exome sequencing (WES, N = 74). EGFR mRNA expression was measured using reverse transcription-polymerase chain reaction (RT-PCR, N = 206) and transcriptome profiling (RNAseq, N = 64). EGFR protein expression was determined by immunohistochemistry (IHC, N = 34). Significant correlations between various methods were determined using Cohen's kappa (k = 0.61 - 0.80 defines substantial agreement) or R2 statistics. EGFR mRNA expression levels by RNAseq and RT-PCR were highly correlated with EGFR amplification assessed by FISH (k = 0.702). High concordance was also observed when comparing FISH to WES (k = 0.739). RNA expression was superior to protein expression in delineating EGFR amplification. Methods for assessing EGFR mRNA expression (RT-PCR, RNAseq) and copy number (WES), but not protein expression (IHC), can be used as surrogates for EGFR amplification (FISH) in GBM. Collectively, our results provide enhanced understanding of available screening options for patients, which may help guide EGFR-targeted therapy approaches.-
dc.language.isoeng-
dc.titleComparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.-
dc.typeJournal Article-
dc.identifier.journaltitleClinical Cancer Research-
dc.identifier.affiliationNeurology, Columbia University Irving Medical Center-
dc.identifier.affiliationOncology Discovery, AbbVie Inc-
dc.identifier.affiliationAbbott Molecular, Abbott (United States)-
dc.identifier.affiliationAbbVie Inc-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationNorthwestern University Feinberg School of Medicine-
dc.identifier.affiliationLa Trobe University, Melbourne, Victoria, Australia-
dc.identifier.affiliationAbbVie Laboratories-
dc.identifier.affiliationR460, AbbVie, Inc-
dc.identifier.affiliationDepartment of Neurology, Erasmus MC Cancer Institute-
dc.identifier.doi10.1158/1078-0432.CCR-18-3034-
dc.identifier.orcid0000-0001-7319-8546-
dc.identifier.orcid0000-0001-5710-5127-
dc.identifier.orcid0000-0002-6656-295X-
dc.identifier.pubmedid30796037-
dc.type.austinJournal Article-
local.name.researcherGan, Hui K
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.